Sarepta Therapeutics Stock Income Statements

Sarepta Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Sarepta Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-07-22	2013-06-30	2012-12-31	2012-09-30	2012-07-22	2011-12-31	2011-07-22	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-07-22	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-07-22	2009-07-22	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-07-22	2008-06-30	2007-07-22	2007-07-22	2006-07-22	2005-12-31	2005-07-22	2005-06-30	2004-12-31	2004-09-30	2004-07-22	2004-03-31	2003-09-30	2003-07-22	2003-07-22	2002-07-22	2002-07-22	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-07-22

revenues:
products	513,123,000	611,523,000	638,157,000	429,771,000	360,548,000	359,484,000	365,071,000	309,322,000	238,988,000	231,495,000	235,933,000	207,774,000	211,237,000	188,825,000	178,725,000	166,911,000	141,839,000	124,926,000	122,644,000	121,429,000	111,344,000	100,448,000
collaboration and other	97,968,000	133,333,000	20,255,000	37,401,000	2,383,000	53,980,000
total revenues	611,091,000	744,856,000	658,412,000	467,172,000	362,931,000	413,464,000	396,781,000	331,817,000	261,238,000	253,500,000	258,427,000	230,269,000	233,487,000	210,830,000	201,461,000	189,406,000	164,089,000	146,931,000	145,138,000	143,924,000	137,363,000	113,674,000	100,113,000	99,041,000	94,668,000	87,011,000	84,415,000	78,486,000	73,529,000	64,604,000	57,277,000	45,954,000	35,011,000	16,342,000
yoy	68.38%	80.15%	65.94%	40.79%	38.93%	63.10%	53.54%	44.10%	11.89%	20.24%	28.28%	21.57%	42.29%	43.49%	38.81%	31.60%	19.46%	29.26%	44.97%	45.32%	45.10%	30.64%	18.60%	26.19%	28.75%	34.68%	47.38%	70.79%	110.02%	295.32%
qoq	-17.96%	13.13%	40.94%	28.72%	-12.22%	4.20%	19.58%	27.02%	3.05%	-1.91%	12.23%	-1.38%	10.75%	4.65%	6.36%	15.43%	11.68%	1.24%	0.84%	4.78%	20.84%	13.55%	1.08%	4.62%	8.80%	3.08%	7.55%	6.74%	13.81%	12.79%	24.64%	31.26%	114.24%
cost and expenses:
cost of sales	152,558,000	137,564,000	132,304,000	91,691,000	44,545,000	50,559,000	44,176,000	37,026,000	34,124,000	35,017,000	30,799,000	39,952,000	37,795,000	31,443,000	31,744,000	23,444,000	19,515,000	22,346,000	22,404,000	15,015,000	13,341,000	12,622,000	15,567,000	13,037,000	15,919,000	12,063,000	13,135,000	8,741,000	6,735,000	5,582,000	3,546,000	3,078,000	534,000	252,000
gross profit	458,533,000	607,292,000	526,108,000	375,481,000	318,386,000	362,905,000	352,605,000	294,791,000	227,114,000	218,483,000	227,628,000	190,317,000	195,692,000	179,387,000	169,717,000	165,962,000	144,574,000	124,585,000	122,734,000	128,909,000	124,022,000	101,052,000	84,546,000	86,004,000	78,749,000	74,948,000	71,280,000	69,745,000	66,794,000	59,022,000	53,731,000	42,876,000	34,477,000	16,090,000
yoy	44.02%	67.34%	49.21%	27.37%	40.19%	66.10%	54.90%	54.89%	16.06%	21.79%	34.12%	14.68%	35.36%	43.99%	38.28%	28.74%	16.57%	23.29%	45.17%	49.89%	57.49%	34.83%	18.61%	23.31%	17.90%	26.98%	32.66%	62.67%	93.73%	266.82%
qoq	-24.50%	15.43%	40.12%	17.93%	-12.27%	2.92%	19.61%	29.80%	3.95%	-4.02%	19.60%	-2.75%	9.09%	5.70%	2.26%	14.79%	16.04%	1.51%	-4.79%	3.94%	22.73%	19.52%	-1.70%	9.21%	5.07%	5.15%	2.20%	4.42%	13.17%	9.85%	25.32%	24.36%	114.28%
gross margin %	75.04%	81.53%	79.91%	80.37%	87.73%	87.77%	88.87%	88.84%	86.94%	86.19%	88.08%	82.65%	83.81%	85.09%	84.24%	87.62%	88.11%	84.79%	84.56%	89.57%	90.29%	88.90%	84.45%	86.84%	83.18%	86.14%	84.44%	88.86%	90.84%	91.36%	93.81%	93.30%	98.47%	98.46%
research and development	204,392,000	773,448,000	199,953,000	224,483,000	179,690,000	200,396,000	195,517,000	194,301,000	241,890,000	245,679,000	213,804,000	216,707,000	252,329,000	194,250,000	197,296,000	139,115,000	239,622,000	195,149,000	207,239,000	190,438,000	188,522,000	136,144,000	223,141,000	133,949,000	113,266,000	90,553,000	146,207,000	86,584,000	122,848,000	46,204,000	44,441,000	34,239,000	58,908,000	29,119,000	70,749,000	34,349,000	44,348,000	38,826,000	41,376,000	36,673,000	29,180,000	39,165,000	30,832,000	21,852,000	20,641,000	20,906,000	410,744,000	21,087,000	13,762,000	12,984,000	346,100,000	10,914,000	14,805,000	285,105,000	15,610,000	17,750,000	14,801,000	244,324,000	9,059,000	9,059,000	6,931,000	6,096,000	6,625,000	7,473,000			5,804,000	4,495,000	5,430,109	7,934,886	7,472,811	8,164,698			6,763,245	4,913,490	4,147,201	3,915,155	3,805,658	4,167,209	97,211,010	6,613,988	3,533,868					7,224,095	7,049,120	38,216,603	2,774,979	36,588,578
selling, general and administrative	137,897,000	133,629,000	163,873,000	128,200,000	138,796,000	127,003,000	131,700,000	120,893,000	118,564,000	110,714,000	120,478,000	104,787,000	154,316,000	71,840,000	78,055,000	61,127,000	72,347,000	71,131,000	86,046,000	75,373,000	73,688,000	82,768,000	81,424,000	75,429,000	67,393,000	60,566,000	64,220,000	53,044,000	47,156,000	43,341,000	32,221,000	28,176,000	36,069,000	26,216,000
amortization of in-licensed rights	667,000	601,000	601,000	602,000	601,000	601,000	763,000	439,000	179,000	178,000	179,000	178,000	179,000	178,000	179,000	178,000	179,000	170,000	165,000	166,000	165,000	166,000	200,000	216,000	217,000	216,000	216,000	216,000	217,000	216,000	216,000	780,000
total cost and expenses	495,514,000	1,045,242,000	496,731,000	444,976,000	363,632,000	378,559,000	372,156,000	352,659,000	394,757,000	391,588,000	365,260,000	361,624,000	444,619,000	297,711,000	307,274,000	223,864,000	331,663,000	298,796,000	315,854,000	280,992,000	275,716,000	231,700,000	330,332,000	222,631,000	370,035,000	163,398,000					80,424,000	91,861,000	98,350,000	55,587,000
operating income	115,577,000	-300,386,000	161,681,000	22,196,000	-701,000	34,905,000	24,625,000	-20,842,000	-133,519,000	-138,088,000	-106,833,000	-131,355,000	-211,132,000	-86,881,000	-105,813,000	-34,458,000	-167,574,000	-151,865,000	-170,716,000	-137,068,000	-138,353,000	-118,026,000	-230,219,000	-123,590,000	-275,367,000	-76,387,000	-139,363,000	-70,099,000	-103,427,000	-30,739,000	-23,147,000	-45,907,000	-63,339,000	-39,245,000	-88,395,000	-56,533,000	-62,100,000	-59,702,000	-64,452,000	-51,763,000	-42,107,000	-61,862,000	-44,722,000	-33,675,000	-30,271,000	-25,121,000	-393,517,000	-24,933,000	-15,415,000	-17,087,000	-341,332,000	-6,905,000	-6,874,000	-304,038,000	-11,271,000	-10,125,000	-5,531,000
yoy	-16587.45%	-960.58%	556.57%	-206.50%	-99.47%	-125.28%	-123.05%	-84.13%	-36.76%	58.94%	0.96%	281.20%	25.99%	-42.79%	-38.02%	-74.86%	21.12%	28.67%	-25.85%	10.91%	-49.76%	54.51%	65.19%	76.31%	166.24%	148.50%	502.08%	52.70%	63.29%	-21.67%	-73.81%	-18.80%	2.00%	-34.27%	37.15%	9.22%	47.48%	-3.49%	44.12%	53.71%	39.10%	146.26%	-88.64%	35.06%	96.37%	47.02%	15.29%	261.09%	124.25%	-94.38%	2928.41%	-31.80%	24.28%
qoq	-138.48%	-285.79%	628.42%	-3266.33%	-102.01%	41.75%	-218.15%	-84.39%	-3.31%	29.26%	-18.67%	-37.79%	143.01%	-17.89%	207.08%	-79.44%	10.34%	-11.04%	24.55%	-0.93%	17.22%	-48.73%	86.28%	-55.12%	260.49%	-45.19%	98.81%	-32.22%	236.47%	32.80%	-49.58%	-27.52%	61.39%	-55.60%	56.36%	-8.96%	4.02%	-7.37%	24.51%	22.93%	-31.93%	38.33%	32.80%	11.25%	20.50%	-93.62%	1478.30%	61.75%	-9.79%	-94.99%	4843.26%	0.45%	-97.74%	2597.52%	11.32%	83.06%
operating margin %	18.91%	-40.33%	24.56%	4.75%	-0.19%	8.44%	6.21%	-6.28%	-51.11%	-54.47%	-41.34%	-57.04%	-90.43%	-41.21%	-52.52%	-18.19%	-102.12%	-103.36%	-117.62%	-95.24%	-100.72%	-103.83%	-229.96%	-124.79%	-290.88%	-87.79%	-165.09%	-89.31%	-140.66%	-47.58%	-40.41%	-99.90%	-180.91%	-240.15%
other income, net:
other income	38,061,000	-83,132,000	10,062,000	11,810,000	14,278,000	6,543,000	15,746,000	-12,332,000	16,934,000	12,707,000	5,527,000	-6,322,000	-16,961,000	-17,265,000	-16,076,000	-20,649,000	-16,185,000	-15,528,000	-17,769,000	-14,335,000	-12,447,000	-7,420,000	-4,773,000	-2,510,000	-862,000		-4,167,750	-6,968,000	-5,218,000	-4,485,000																																			4,495,000	4,495,000							6,317,641	6,317,641										2,805,895	2,805,895	65,614,102	65,614,102
income before income tax expense	153,638,000	-383,518,000	171,743,000	34,006,000	13,577,000	41,448,000	-140,117,250	-33,174,000	-14,585,000	-512,710,000									-91,145,000	-196,403,000	-150,800,000	-17,377,000	-119,722,000	-126,100,000	-276,229,000	-76,559,000				-35,224,000	-25,840,000	-45,723,000		86,090,000
income tax (benefit) expense	-43,254,000																-354,000	-143,000									-779,000	-674,000					-109,000
net income	196,892,000	-447,508,000	159,049,000	33,611,000	6,460,000	36,119,000	45,655,000	-40,937,000	-23,940,000	-516,755,000	-109,244,000	-257,738,000	-231,481,000	-105,025,000	-121,981,000	-48,144,000	-81,405,000	-167,250,000	-189,317,000	-196,499,000	-150,820,000	-17,492,000	-235,703,000	-126,326,000	-276,403,000	-76,643,000	-140,895,000	-76,393,000	-109,267,000	-35,363,000	-23,998,000	-47,734,000	-63,046,000	84,090,000	-88,452,000	-56,742,000	-62,301,000	-59,770,000	-64,681,000	-51,939,000	-41,851,000	-61,559,000	-44,416,000	-29,226,000	-33,874,000	-28,273,000	-440,071,000	-42,030,000	-42,084,000	-19,051,000	-372,031,000	-49,554,000	-17,704,000				1,833,000					-584,000	3,525,000	-8,090,000			-19,668,000	-927,000	-1,140,534	-6,046,993	-15,014,476	-1,750,622			-9,061,150	-4,551,572	-1,692,471	-4,932,642	-4,990,254	-5,106,966	-145,875,160	-7,532,512	-4,603,655					-10,497,859	-7,816,093	-64,898,088	-15,596,194	-63,472,543
yoy	2947.86%	-1338.98%	248.37%	-182.10%	-126.98%	-106.99%	-141.79%	-84.12%	-89.66%	392.03%	-10.44%	435.35%	184.36%	-37.20%	-35.57%	-75.50%	-46.03%	856.15%	-19.68%	55.55%	-45.43%	-77.18%	67.29%	65.36%	152.96%	116.73%	487.11%	60.04%	73.31%	-142.05%	-72.87%	-15.88%	1.20%	-240.69%	36.75%	9.25%	48.86%	-2.91%	45.63%	77.72%	23.55%	117.73%	-89.91%	-30.46%	-19.51%	48.41%	18.29%	-15.18%	137.71%				-1065.85%										-117.92%	772.71%			30.99%	-47.05%			65.70%	-61.54%			81.58%	-10.88%	-98.84%	-34.52%	8.40%									-83.46%
qoq	-144.00%	-381.36%	373.21%	420.29%	-82.11%	-20.89%	-211.53%	71.00%	-95.37%	373.03%	-57.61%	11.34%	120.41%	-13.90%	153.37%	-40.86%	-51.33%	-11.66%	-3.65%	30.29%	762.22%	-92.58%	86.58%	-54.30%	260.64%	-45.60%	84.43%	-30.09%	208.99%	47.36%	-49.73%	-24.29%	-174.97%	-195.07%	55.88%	-8.92%	4.23%	-7.59%	24.53%	24.10%	-32.01%	38.60%	51.97%	-13.72%	19.81%	-93.58%	947.04%	-0.13%	120.90%	-94.88%	650.76%	179.90%										-116.57%	-143.57%				2021.68%	-18.72%	-81.14%	-59.73%	757.67%				99.08%	168.93%	-65.69%	-1.15%	-2.29%	-96.50%	1836.61%	63.62%						34.31%	-87.96%	316.11%	-75.43%
net income margin %	32.22%	-60.08%	24.16%	7.19%	1.78%	8.74%	11.51%	-12.34%	-9.16%	-203.85%	-42.27%	-111.93%	-99.14%	-49.82%	-60.55%	-25.42%	-49.61%	-113.83%	-130.44%	-136.53%	-109.80%	-15.39%	-235.44%	-127.55%	-291.97%	-88.08%	-166.91%	-97.33%	-148.60%	-54.74%	-41.90%	-103.87%	-180.07%	514.56%
other comprehensive income:
unrealized gains on investments, net of tax	-85,000	252,000	-2,463,000	3,275,000	-339,000	-1,609,000	1,556,000	417,000	-636,000	1,245,000			-2,179,000				5,000	-6,000	-14,000	-12,000	-618,000	574,000
total other comprehensive income	-85,000	252,000	-2,463,000	3,275,000	-339,000	-1,609,000	1,556,000	417,000	-636,000	1,245,000								-6,000	9,000	-12,000	-618,000	574,000	-25,000	-7,000	63,000	118,000	96,750	369,000	282,000	-264,000	27,000	26,000	17,000	65,000	27,750	-1,000	6,000	106,000	23,500	18,000	-2,000				24,000
comprehensive income	196,807,000	-447,256,000	156,586,000	36,886,000	6,121,000	34,510,000																							-108,985,000	-35,627,000			-63,029,000	84,155,000																-19,051,000	-14,805,000	-49,554,000	-17,704,000
earnings per share:
basic	2.01	-4.6	1.67	0.35	0.07	0.38
diluted	1.89	-4.6	1.56	0.34	0.07	0.37
weighted-average number of shares of common stock used in computing earnings per share:
basic	98,005	97,362	95,075	95,390	94,618	93,991
diluted	106,623	97,362	107,875	100,448	99,144	99,114
income tax expense		63,990,000	12,694,000	395,000	7,117,000	5,329,000	5,290,750	7,763,000	9,355,000	4,045,000									57,750	96,000	20,000	115,000			174,000	84,000				139,000	-1,842,000	2,011,000		2,000,000
gain from sale of priority review voucher									102,000,000								102,000,000					108,069,000												125,000,000																															-927,000	-927,000							-9,722,975	-9,722,975										-3,418,817	-3,418,817	-112,584,224	-112,584,224
loss on debt extinguishment										-387,329,000		-125,441,000
total other income			10,062,000	11,810,000	14,278,000	6,543,000			118,934,000		5,527,000	-125,063,000	-16,961,000		-16,076,000	-13,449,000	85,815,000	-15,528,000	-17,769,000	-59,335,000	-12,447,000	100,649,000									-2,693,000	184,000	184,000	125,335,000	-57,000	-209,000	-201,000	-68,000	-229,000	-176,000	256,000	303,000	-576,500	4,449,000
collaboration							16,687,500	22,495,000	22,250,000	22,005,000	16,687,500	22,495,000	22,250,000	22,005,000	16,687,500	22,495,000	22,250,000	22,005,000	22,494,000	22,495,000	26,019,000	13,226,000
other loss, net:
total other loss							-67,005,000	-12,332,000		-374,622,000				-17,265,000																															-3,603,000	-3,152,000	-11,432,500	-17,097,000
comprehensive loss							47,211,000	-40,520,000	-24,576,000	-515,510,000	-107,703,000	-258,458,000	-233,660,000	-105,311,000	-121,981,000	-48,166,000	-81,400,000	-167,256,000	-189,308,000	-196,511,000	-151,438,000	-16,918,000	-235,728,000	-126,333,000	-276,340,000	-76,525,000	-141,002,000	-76,024,000			-24,365,000	-47,708,000			-88,572,000	-56,743,000	-62,295,000	-59,664,000	-64,791,000	-51,921,000	-41,853,000	-61,481,000	-44,456,000	-29,247,000	-33,850,000	-28,332,000	-440,071,000	-42,030,000	-42,084,000
net income per share							0.76	-0.46	-0.27	-5.86	-1.24	-2.94	-2.65	-1.2	-1.43	-0.6	-1.02	-2.1	-2.41	-2.5	-1.93	-0.23	-3.17	-1.7	-3.74	-1.07	-2.08	-1.15			-0.39	-0.78			-1.66	-1.18	-1.35	-1.31	-1.45	-1.25		-1.49	-1.08	-0.71	-0.85	-0.75	-0.793	-1.24	-1.32	-0.6	-0.653	-2.17	-0.13	-0.003	-0.03	0.01	0.02	-0.055	-0.07	-0.07	-0.15	-0.01	0.06	-0.08			-0.23	-0.01	-0.01	-0.08	-0.23	-0.02			-0.18	-0.09	-0.04	-0.11	-0.14	-0.14		-0.21	-0.15					-0.4	-0.33	-0.253	-0.67
weighted-average number of shares of common stock used in computing basic and diluted net income per share							92,398	88,889	88,743	88,186	87,559	87,628	87,511	87,253	81,262	79,880	79,746	79,454	77,956	78,501	77,968	76,432	73,615	74,177	73,958	71,731		66,209
settlement and license charges																		10,000,000														25,588,000
gain on contingent consideration												6,700,000				7,200,000
income before income tax benefit											-101,306,000	-256,418,000	-228,093,000	-104,146,000	-74,264,750	-47,907,000													-108,645,000
income tax benefit											7,938,000	1,320,000	3,388,000	879,000	-65,000	237,000							711,000	226,000					622,000
other comprehensive loss:
unrealized losses on investments, net of tax											1,541,000	-720,000		-286,000	-5,750	-22,000
total other comprehensive loss											1,541,000	-720,000	-2,179,000	-286,000	-5,750	-22,000	5,000																										-40,000	-21,000		-59,000
other income:
income before income tax (benefit) expense																	-81,759,000	-167,393,000									-141,674,000	-77,067,000					-63,155,000
acquired in-process research and development																									173,240,000																										29,461,000	0	0																		9,916,271										19,545,028											19,545,028
loss on contingent consideration																				-45,000,000																																													-0.01	-0.01							-0.18	-0.18										-0.13	-0.13
product																							100,113,000	99,041,000	94,668,000	87,011,000	84,415,000	78,486,000	73,529,000	64,604,000	57,277,000	45,954,000	35,011,000	16,342,000
other loss:
other loss																							-886,000	-2,510,000	-862,000	-172,000
unrealized gains on investments																							-25,000	-7,000	63,000
interest expense and other																										-172,000
unrealized gain on cash equivalents and short-term investments																										118,000	96,750	369,000	282,000	-264,000	27,000	26,000
costs and expenses:
exondys 51 litigation and license charges																																	2,839,000
total costs and expenses																											105,221,000	148,585,000	176,956,000	95,343,000
interest income and other																											-4,167,750	-6,968,000	-5,218,000	-4,485,000	-2,693,000	184,000	184,000	335,000	-57,000	-209,000	-201,000	-68,000	-229,000	-176,000	256,000	303,000	306,000	193,000	181,000	99,000	9,568,000	63,000	237,000	-19,000	9,253,000	67,000	96,000	8,729,000	199,000	151,000	90,000	8,412,000	82,000	82,000	51,000	42,000						16,000
basic earnings per share																													-1.67	-0.55			-1.15	1.53																																																				19,545,028	19,545,028
diluted earnings per share																													-1.67	-0.55			-1.15	1.5
weighted-average number of shares of common stock used in computing:
weighted-average number of shares of common stock outstanding for computing basic and diluted net income per share																											66,250				58,818	61,528			48,697	48,254	46,157	45,697	42,290	41,565	41,357
unrealized gain on short-term securities - available-for-sale																																	17,000	65,000	27,750	-1,000	6,000	106,000	23,500	18,000	-2,000
weighted-average number of shares of common stock used in calculating:
revenues
operating expenses:
general and administrative																																			15,203,000	22,184,000	17,752,000	20,876,000	24,329,000	15,090,000	12,927,000	22,697,000	13,917,000	12,882,000	12,213,000	10,303,000	129,486,000	8,014,000	6,127,000	7,054,000	109,326,000	3,565,000	3,281,000	92,286,000	3,185,000	3,960,000	5,026,000	77,385,000	3,440,000	3,440,000	4,733,000	2,844,000	2,470,000	1,800,000			2,206,000	2,220,000	2,943,530	3,173,942	1,982,679	1,696,796			2,821,726	1,409,066	1,052,244	1,272,529	1,416,803	964,700	25,503,904	1,238,201	1,560,026					895,706	1,084,519	12,275,514	877,615	12,433,101
total operating expenses																																			44,583,750	56,533,000	62,100,000	59,702,000	65,705,000	51,763,000	42,107,000	61,862,000
revenue from research contracts and other grants																																											27,000	1,059,000	2,583,000
gain on change in warrant valuation																																											-694,750	4,256,000							-26,814,000	-42,716,000	-10,926,000												16,000	16,000
loss on change in warrant valuation																																													-3,784,000	-3,251,000	-11,502,750	-17,160,000
loss per share — basic and diluted																																									-1.01
unrealized gain on available-for-sale securities																																										78,000			24,000
total other comprehensive gain																																										78,000
weighted-average number of common shares outstanding for computing basic and diluted net income per share																																										41,324				37,821			31,813
unrealized loss on available-for-sale securities																																											-13,750	-21,000		-59,000
weighted-average number of common stock outstanding for computing basic and diluted net income per share																																											40,026	41,066	39,862
revenue from license fees, grants and research contracts																																														6,088,000
realized gain on sale of available-for-sale securities																																																																	2,220,000	2,220,000							4,303,885	4,303,885										933,401	933,401	17,816,311	17,816,311
write-down of available-for-sale securities
revenues from license fees, grants and research contracts																																															176,174,000	4,168,000	4,474,000	2,951,000	143,555,000	7,574,000	11,212,000	102,814,000	7,524,000	11,585,000	14,296,000	75,326,000	8,702,000	8,702,000	3,997,000	1,205,000	5,141,000	6,349,000			2,945,000	3,150,000	5,479,912	5,170,663	5,624,617	4,982,963			65,962	1,417,446	3,281,805	39,317	285,588	9,151
realized gain on sale of short-term securities — available-for-sale
write-down of short-term securities — available-for-sale
unrealized loss on short-term securities — available-for-sale
weighted-average number of common shares outstanding for computing basic net income per share																																																33,943
weighted-average number of common shares outstanding for computing diluted net income per share																																																33,943
other non-operating income:
loss on change in warrant liability																																																	-26,906,000
income on change in warrant valuation																																																		-1,945,000
weighted-average number of common shares outstanding for computing basic income per share																																																		31,984		22,824	135,743			134,090	112,482
weighted-average number of common shares outstanding for computing diluted income per share																																																		31,984		22,824	135,743			138,916	121,285
realized gain on sale of short-term securities— available-for-sale																																																				0
write-down of short-term securities— available-for-sale																																																				0													3,150,000	3,150,000							536,042	536,042
unrealized loss on short-term securities— available-for-sale																																																				0
realized gain on sale of short-term securities - available-for-sale																																																					0
write-down of short-term securities - available-for-sale																																																					0
unrealized loss on short-term securities - available-for-sale																																																					0
increase on warrant valuation																																																						6,394,750	7,052,000	11,253,000	7,274,000					7,109,000
realized gain on sale of short-term securities—available-for-sale																																																																																	3,862,502
write-down of short-term securities—available-for-sale
net income and comprehensive loss																																																						-227,000	-4,020,000			-6,133,250	-7,293,000	-7,293,000	-16,656,000
weighted-average number of common shares outstanding for computing basic and diluted loss per share																																																							135,738				111,767	111,767	110,383	110,429	93,090	95,261			85,664	80,759	69,491,475	71,150,972	65,321,986	70,985,520			51,715,050	44,655,008	44,184,293	44,167,565	35,994,976	36,123,790		35,610,687	31,186,464					26,353,017	23,442,127		23,122,839
realized gain on sale of short-term—securitiesavailable-for-sale
net income and comprehensive income																																																								1,279,000
gain on warrant liability																																																																				2,622,000	1,717,277			3,047,459
interest income and other loss
increase on warrant liability
interest income																																																																					35,916	60,147	167,352	80,450			457,859	353,538	225,169	215,725	-53,381	15,792	4,736,599	220,226	75,887					111,207	79,851	2,608,443	271,939	2,842,879
revenues, from license fees, grants and research contracts																																																																																	4,787,029	99,451	414,352					197,691		2,433,864	307,549	2,154,535
realized gain on sale of short-term securities																																																																																												96,750
write-down of short-term securities–available-for-sale
revenues, from license fees, grants and
research contracts																																																																																									237,695
write-down of short-term securities--available-for-sale																																																																	80,759	80,759							53,241,730	53,241,730										26,567,968	26,567,968
3,556,746																																																																																												68,566,707
362,056																																																																																												2,939,629

We provide you with 20 years income statements for Sarepta Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sarepta Therapeutics stock. Explore the full financial landscape of Sarepta Therapeutics stock with our expertly curated income statements.

The information provided in this report about Sarepta Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.